What Is Female Pattern Hair Loss?
Female pattern hair loss, known clinically as female androgenetic alopecia, is a progressive form of hair thinning that follows a characteristic distribution across the top and crown of the scalp. Unlike male pattern baldness, which typically produces a receding hairline and discrete bald areas, female pattern hair loss tends to present as a diffuse reduction in density with preservation of the frontal hairline. This means it can be easy to dismiss or attribute to other factors in its earlier stages, and many women spend considerable time managing the cosmetic effects before receiving a clear explanation of what is happening.
The condition shares the same biological mechanism as its male counterpart: a sensitivity in genetically predisposed hair follicles to dihydrotestosterone (DHT), which causes progressive follicular miniaturisation. However, the hormonal landscape in women is more complex. Oestrogen plays a significant moderating role in follicle health, and the reduction in oestrogen levels that accompanies perimenopause and menopause frequently accelerates the thinning that genetic predisposition had already set in motion. This is why female pattern hair loss so often comes to clinical attention during or after the menopausal transition, even when the underlying predisposition has been present for years.
Female pattern hair loss is not a reflection of poor health or inadequate care. It is a recognised medical condition with clear biological drivers, meaningful treatment options, and a well-established clinical framework for assessment and management. For women across Birmingham and the West Midlands who are experiencing this, seeking a proper assessment is both a practical and validating step.
Female pattern hair loss follows the Ludwig classification, which describes three stages of increasing severity: stage I involves a subtle widening of the central parting; stage II shows more noticeable diffuse thinning across the crown; stage III presents as near-complete loss of density over the top of the scalp. The frontal hairline is typically preserved throughout, which distinguishes female pattern hair loss from the frontal recession seen in male pattern baldness.
Symptoms
The signs of female pattern hair loss often develop gradually and can be easy to overlook or attribute to styling, seasonal change, or stress. Common symptoms include:
- A progressive widening of the central parting, often one of the earliest visible signs
- Diffuse reduction in hair density and volume across the crown and top of the scalp
- The scalp becoming increasingly visible under bright or overhead lighting, particularly when the hair is dry
- Individual hairs feeling finer, shorter, or more fragile than previously, reflecting follicular miniaturisation
- Reduced bulk when the hair is tied back or styled, even though individual hairs may still appear healthy
- Increased hair shedding noticed on the pillow, in the shower, on clothing, or when brushing
- Difficulty achieving the same volume or coverage with styling that was once straightforward
- The ponytail feeling noticeably thinner in circumference over time
Causes
The central mechanism of female pattern hair loss is the same as in men: a genetic sensitivity of certain hair follicles to dihydrotestosterone, which causes those follicles to undergo progressive miniaturisation across successive growth cycles. DHT shortens the anagen (active growth) phase and causes the follicle to produce shorter, finer hairs until production ceases. The follicles most susceptible to this process in women tend to be those across the crown and central scalp rather than the frontal hairline, producing the diffuse rather than receding pattern that characterises the condition.
Oestrogen has an important moderating influence on this process. It promotes the growth phase of the hair cycle, counteracts some of the effects of androgens on the follicle, and generally supports follicle health. During the reproductive years, adequate oestrogen levels provide a natural buffer against DHT-driven miniaturisation in predisposed follicles. As oestrogen declines during perimenopause and menopause, this buffering effect diminishes, and follicles that were always genetically susceptible can begin to miniaturise more rapidly. This is why many women notice the onset or significant worsening of hair thinning during the menopausal transition.
Several additional factors can contribute to or worsen hair thinning in women alongside an underlying androgenetic pattern. Iron deficiency and low ferritin are particularly relevant; ferritin is essential for hair follicle cycling, and levels that are technically within the normal laboratory range may still be suboptimal for hair growth. Thyroid dysfunction, both underactive and overactive, can cause or compound diffuse hair loss. Polycystic ovary syndrome (PCOS), which is associated with elevated androgen levels, can accelerate follicular miniaturisation in susceptible women. Chronic psychological stress, nutritional deficiencies including zinc and certain B vitamins, and restrictive dieting can all impair hair growth and should be considered as part of a comprehensive assessment.
A Note on Common Misconceptions
Female pattern hair loss is frequently misattributed or minimised. It is often told to women that thinning after childbirth or at menopause is "just hormonal" and will resolve on its own; this may be true for postpartum shedding (telogen effluvium), but female androgenetic alopecia is a distinct condition that does not spontaneously reverse. The idea that hair loss in women is always caused by stress or diet is also an oversimplification: while these factors can compound the condition, they are not its root cause. Understanding the distinction between androgenetic alopecia and these secondary causes is central to selecting the right treatment approach.
Low ferritin is among the most commonly identified and most treatable contributors to hair thinning in women. Ferritin levels that are within a laboratory's normal range may still be insufficient to support optimal hair growth. If you have not had your ferritin checked as part of a hair loss assessment, this is worth requesting from your GP, particularly before attributing thinning entirely to androgenetic alopecia.
Who Is Affected?
Female pattern hair loss is far more common than is widely appreciated. It affects women across all age groups, though the likelihood of experiencing it increases with age. A meaningful proportion of women begin to notice signs during their thirties and forties, and prevalence rises substantially after the menopause, when the protective influence of oestrogen on follicle health diminishes.
Unlike male pattern baldness, which tends to follow a fairly predictable timeline from onset, female pattern hair loss often progresses more slowly and with greater variability. Some women experience a gradual, barely perceptible reduction in density over many years; others notice a more marked change coinciding with a specific hormonal event such as stopping the combined oral contraceptive pill, delivering a baby, or entering perimenopause.
A family history on either side is the strongest risk factor, confirming the genetic basis of the condition. Women with polycystic ovary syndrome face an elevated risk due to higher circulating androgen levels. Women of all ethnic backgrounds can be affected, though the pattern and rate of progression can vary. Importantly, the psychological impact of female pattern hair loss should not be underestimated: research consistently shows that hair thinning can have a significant effect on self-esteem, identity, and quality of life, and this dimension is taken seriously at Regener8 Aesthetics.
Women who have recently stopped hormonal contraception may notice a temporary increase in shedding as the body adjusts to the change in hormone levels. This is typically self-limiting, but if thinning persists beyond six months, it is worth seeking an assessment to determine whether an underlying androgenetic pattern has been unmasked by the hormonal change.
Diagnosis and Assessment
A thorough and accurate assessment is the essential starting point for managing female pattern hair loss effectively. Diagnosis is primarily clinical, based on the characteristic pattern and distribution of thinning, the appearance and calibre of individual hairs, and a detailed history covering when the change began, its progression, relevant medical history, and family background. The Ludwig scale is the most commonly used framework for classifying the severity of female pattern hair loss, from early central widening through to more advanced diffuse crown involvement.
A pull test, in which a small cluster of hairs is gently pulled to assess how many detach with minimal traction, provides information about the activity of the current shedding phase. A high yield may suggest a superimposed telogen effluvium (a reactive shedding episode) in addition to the underlying androgenetic pattern.
Trichoscopy, using a dermatoscope to examine the scalp at magnification, can reveal signs of follicular miniaturisation including variation in hair shaft diameter, the presence of vellus hairs in thinning areas, and changes to the follicular openings. This is a useful objective tool both for confirming diagnosis and for monitoring change over time.
Blood tests are frequently relevant in women presenting with hair thinning. Key markers to consider include ferritin and full blood count (to assess iron status), thyroid function including TSH and free T4, and where appropriate, sex hormone levels including testosterone and sex hormone binding globulin (SHBG). In women with features suggesting PCOS, a broader hormonal and metabolic screen may be warranted. Where blood test findings point to a primary medical condition requiring treatment, referral to a GP or specialist will be recommended as the priority. Treating an underlying deficiency first is important: PRP is more likely to be effective in an optimised physiological environment.
Evidence-Based Treatments
No treatment eliminates the genetic predisposition underlying female pattern hair loss, but several approaches have a meaningful evidence base for slowing progression, reducing shedding, and supporting density in follicles that are still biologically active.
First-Line Approaches
Addressing modifiable contributing factors is a sensible first step alongside any active treatment. This includes correcting nutritional deficiencies identified through blood testing, ensuring adequate dietary protein (a component of the keratin that makes up the hair shaft), managing chronic stress where possible, and reviewing any medications that may carry hair loss as a side effect. For women considering or currently using hormonal contraception, discussion with a GP about formulations with a lower androgenic profile may also be relevant where this is contributing to the picture.
Medical Treatments
Topical minoxidil is the most widely studied non-prescription topical treatment for female pattern hair loss. Applied directly to the scalp, it works by prolonging the anagen growth phase and promoting blood supply to the follicles. Evidence supports its use in female androgenetic alopecia, with many women seeing a reduction in shedding and some improvement in density over the course of several months of consistent use. The main limitation is that its effects depend on continued use; stopping typically leads to a return of shedding within months. For women of childbearing age, minoxidil should not be used during pregnancy.
Oral finasteride and dutasteride are used off-label in some postmenopausal women under specialist supervision, working by reducing DHT through inhibition of the 5-alpha reductase enzyme. These are prescription-only medications and are not appropriate for premenopausal women due to the risk of harm in pregnancy. Any consideration of these options should involve a prescribing GP or dermatologist with experience in female hair loss. Regener8 Aesthetics does not prescribe these medications but can discuss their role and facilitate appropriate referral.
For women in perimenopause or post-menopause, hormone replacement therapy (HRT) can have a positive indirect effect on hair by restoring some of the oestrogen-mediated protection of the follicles. HRT is a decision to be made with a GP or gynaecologist in the context of an individual's overall health and risk profile; it is not a hair treatment per se, but it can meaningfully support the environment in which other hair treatments operate.
PRP Therapy for Hair Loss
Platelet-Rich Plasma therapy is one of the most evidenced non-surgical options available for female pattern hair loss, and women often respond particularly well to it. The treatment involves drawing a small sample of blood, concentrating the platelet-rich component through centrifugation, and injecting the resulting preparation into the scalp at follicle level. The growth factors released by the concentrated platelets can stimulate follicle activity, improve local blood supply, and support the transition of follicles from resting back to active growth phases.
PRP is most effective in women whose follicles are miniaturising but still biologically active, which describes the majority of those in the early-to-moderate stages of female pattern hair loss. Unlike areas of complete permanent baldness, where follicles have closed entirely, the diffuse thinning characteristic of female androgenetic alopecia typically involves follicles that retain some capacity to respond to growth stimulation. This makes women with this pattern well-suited candidates for PRP in many cases.
At Regener8 Aesthetics in Selly Oak, Birmingham, an initial course of three PRP sessions is recommended for most patients, spaced four to six weeks apart. Follow-up maintenance sessions every three to six months help to sustain the results achieved. Full results are typically assessed at the six-month mark from the start of treatment. The procedure is carried out in a clinical setting with a topical numbing cream applied before the injections to ensure comfort throughout.
Microneedling
Scalp microneedling creates a pattern of controlled micro-channels in the skin, which triggers a localised healing response and stimulates the production of growth factors within the dermis. As an adjunct to PRP, microneedling can enhance the absorption of the platelet-rich preparation and amplify the overall stimulus to the follicles. It is well tolerated and fits naturally into a combination treatment approach. Some practitioners also combine microneedling with topical minoxidil to improve its penetration into the scalp. As a standalone treatment for female androgenetic alopecia, evidence is less established than for PRP, but its role as part of a wider programme is increasingly recognised.
Combination Approaches
A combination strategy is likely to produce the best outcomes for most women with female pattern hair loss. A typical programme might include topical minoxidil applied consistently at home, PRP sessions at the clinic, and where appropriate in postmenopausal women, consideration of HRT in discussion with a GP. Each element addresses a different aspect of the condition: minoxidil extends the growth phase, PRP stimulates follicle activity directly, and HRT may help to restore some of the hormonal environment that supports follicle health. The right combination for any individual depends on her stage of hair loss, hormonal status, overall health, and personal priorities.
When Treatment May Not Be Appropriate
PRP is not appropriate during pregnancy, for those with active scalp infections, certain blood or immune disorders, or those on anticoagulant therapy. In very advanced cases where thinning has progressed to near-complete crown loss and follicles have been dormant for many years, PRP is unlikely to produce meaningful results, and this will be communicated clearly during consultation. For women at this stage, a referral for specialist dermatological review may be more appropriate. There is no benefit to beginning a treatment programme that is not suited to the clinical picture, and this clinic does not operate on that basis.
Book a £25 consultation at Regener8 Aesthetics in Selly Oak, Birmingham. The fee is fully redeemable against any treatment booked within 30 days. No pressure to proceed. Consultations available in English, Farsi and Russian.
Finance available, subject to approval, via our Payl8r finance partner.
Why Choose Regener8 Aesthetics?
Evidence-based practice. At Regener8 Aesthetics, treatments are selected and recommended on the basis of clinical evidence. Women presenting with hair thinning receive an honest and thorough assessment of their options, with clear communication about what is realistic for their particular pattern and stage of loss. We do not offer treatments that lack a credible foundation, and we are straightforward when a treatment is unlikely to benefit a specific presentation.
Clinical healthcare background. Our lead practitioner's clinical healthcare background informs every aspect of the consultation and treatment experience. Hair loss in women frequently involves overlapping causes, and the ability to take a thorough clinical history, identify when blood tests or onward referral are appropriate, and communicate complex information clearly is central to the quality of care we provide.
Patient-centred care. Female pattern hair loss affects more than the appearance. It is a condition that can touch deeply on identity, confidence, and emotional wellbeing. Consultations at Regener8 Aesthetics are approached with an awareness of this dimension. The conversation does not stop at follicles and growth factors; the whole person and her experience are part of what we take seriously.
Unhurried consultations. Appointments are structured to allow proper time for history-taking, examination, explanation of findings, and discussion of options. Women who come to us having received limited information elsewhere often find the consultation itself valuable, regardless of whether they proceed to treatment. There is never any pressure to commit on the day.
Multilingual consultations. The clinic offers consultations in English, Farsi, and Russian. For clients across Birmingham and the wider West Midlands for whom English is not a first language, this means being able to discuss something personal and medically nuanced with genuine clarity, without the need to simplify or set aside important detail.
- Female pattern hair loss is driven by a genetic sensitivity of hair follicles to DHT, frequently accelerated by falling oestrogen levels during perimenopause and menopause.
- The condition presents as diffuse thinning across the crown with frontal hairline preservation, distinguishing it from the recession seen in male pattern baldness.
- Contributory factors including low ferritin, thyroid dysfunction, and hormonal imbalances are worth investigating before and alongside any active treatment programme.
- PRP therapy is well-suited to women with early-to-moderate female pattern hair loss, where follicles remain biologically active and capable of responding to growth factor stimulation.
- A combination approach using topical minoxidil, PRP, and where appropriate hormonal management tends to produce better outcomes than any single treatment used in isolation.